SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185 – ExecEdge
Now Reading:
SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185
Full Article 50 second read

SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

By Exec Edge Editorial Staff

SAB Biotherapeutics (Nasdaq: SABS) said it saw positive results from a Phase 3 clinical trial that assessed its Covid-19 drug, SAB-185, in non-hospitalized people who were at high-risk for severe outcomes.

SAB-185 demonstrated benefit in sustained symptom resolution in study participants with Covid-19 caused by Omicron as compared to participants who received a monoclonal antibody combination, REGEN-COV, it said in a statement.

Two-thirds of participants treated with SAB-185 reached full symptom resolution for at least four consecutive days by Day 28, while only 50% of participants on REGEN-COV met this endpoint, and the median time to symptom resolution for at least 4 consecutive days was seven days shorter for SAB-185, the company said.

The median time to symptom resolution for at least two consecutive days was six days shorter for SAB-185, as compared to those who were treated with REGEN-COV, it said.

 

Contact:

Executives-edge.com

Editor@Executives-edge.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Input your search keywords and press Enter.